Qualigen Therapeutics Stock Probability of Future Stock Price Finishing Over 79.49

QLGN Stock  USD 3.87  0.11  2.93%   
Qualigen Therapeutics' future price is the expected price of Qualigen Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Qualigen Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Qualigen Therapeutics Backtesting, Qualigen Therapeutics Valuation, Qualigen Therapeutics Correlation, Qualigen Therapeutics Hype Analysis, Qualigen Therapeutics Volatility, Qualigen Therapeutics History as well as Qualigen Therapeutics Performance.
To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.
  
As of the 14th of December 2024, Price To Sales Ratio is likely to drop to 25.45. In addition to that, Price Earnings Ratio is likely to drop to -10.91. Please specify Qualigen Therapeutics' target price for which you would like Qualigen Therapeutics odds to be computed.

Qualigen Therapeutics Target Price Odds to finish over 79.49

The tendency of Qualigen Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 79.49  or more in 90 days
 3.87 90 days 79.49 
close to zero percent
Based on a normal probability distribution, the odds of Qualigen Therapeutics to move over $ 79.49  or more in 90 days from now is close to zero percent (This Qualigen Therapeutics probability density function shows the probability of Qualigen Stock to fall within a particular range of prices over 90 days) . Probability of Qualigen Therapeutics price to stay between its current price of $ 3.87  and $ 79.49  at the end of the 90-day period is about 88.88 .
Given the investment horizon of 90 days Qualigen Therapeutics has a beta of 0.7 indicating as returns on the market go up, Qualigen Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Qualigen Therapeutics will be expected to be much smaller as well. Additionally Qualigen Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Qualigen Therapeutics Price Density   
       Price  

Predictive Modules for Qualigen Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Qualigen Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.173.4010.22
Details
Intrinsic
Valuation
LowRealHigh
3.4812.8619.68
Details
1 Analysts
Consensus
LowTargetHigh
36.4040.0044.40
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.000.000.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Qualigen Therapeutics. Your research has to be compared to or analyzed against Qualigen Therapeutics' peers to derive any actionable benefits. When done correctly, Qualigen Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Qualigen Therapeutics.

Qualigen Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Qualigen Therapeutics is not an exception. The market had few large corrections towards the Qualigen Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Qualigen Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Qualigen Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.93
β
Beta against Dow Jones0.70
σ
Overall volatility
2.00
Ir
Information ratio -0.14

Qualigen Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Qualigen Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Qualigen Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Qualigen Therapeutics generated a negative expected return over the last 90 days
Qualigen Therapeutics has high historical volatility and very poor performance
Qualigen Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 5.2 M. Net Loss for the year was (12.48 M) with profit before overhead, payroll, taxes, and interest of 680.8 K.
Qualigen Therapeutics currently holds about 6.62 M in cash with (10.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57.
Latest headline from gurufocus.com: Qualigen Therapeutics Announces Regained Compliance with Nasdaqs Minimum Bid Price Requirement ...

Qualigen Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Qualigen Stock often depends not only on the future outlook of the current and potential Qualigen Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Qualigen Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding5.1 M
Cash And Short Term Investments401.8 K

Qualigen Therapeutics Technical Analysis

Qualigen Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Qualigen Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Qualigen Therapeutics. In general, you should focus on analyzing Qualigen Stock price patterns and their correlations with different microeconomic environments and drivers.

Qualigen Therapeutics Predictive Forecast Models

Qualigen Therapeutics' time-series forecasting models is one of many Qualigen Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Qualigen Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Qualigen Therapeutics

Checking the ongoing alerts about Qualigen Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Qualigen Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Qualigen Therapeutics generated a negative expected return over the last 90 days
Qualigen Therapeutics has high historical volatility and very poor performance
Qualigen Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 5.2 M. Net Loss for the year was (12.48 M) with profit before overhead, payroll, taxes, and interest of 680.8 K.
Qualigen Therapeutics currently holds about 6.62 M in cash with (10.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57.
Latest headline from gurufocus.com: Qualigen Therapeutics Announces Regained Compliance with Nasdaqs Minimum Bid Price Requirement ...
When determining whether Qualigen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Qualigen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Qualigen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Qualigen Therapeutics Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
3.6 K
Revenue Per Share
1.034
Quarterly Revenue Growth
0.137
Return On Assets
(0.75)
Return On Equity
(8.42)
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.